Origins of cardiac dysfunction in cirrhosis

Gut

Volumn 52, Issue 10, 2003, Pages 1392-1394

  Jimenez W ^a,b   Arroyo, V ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE FUNCTION; HEART VOLUME; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; MOLECULAR MECHANICS; NOTE; PRIORITY JOURNAL;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BLOOD CIRCULATION; CARDIOVASCULAR DISEASES; HEART; HUMANS; LIVER CIRRHOSIS; NATRIURETIC PEPTIDE, BRAIN;

EID: 0141757446     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.10.1392     Document Type: Note

References (33)

1. Arroyo V, Jiménez W. Renal and circulatory dysfunction in cirrhosis. Lights and shadows in an important clinical problem. J Hepatology 2000;32(suppl 1):157-70.
2. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122:1658-76.
3. Müller C, Schenk P. Hepatopulmonary syndrome. Wien Klin Wochenschr 1999;111:339-47.
4. Blendis L, Wong F. Is there a cirrhotic cardiomyopathy? Am J Gastroenterology 2000;11:3026-8.
5. Moller S, Sendergaard L, Mogelvang J, et al. Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology 1995;22:472-8.
6. Laffi G, Barletta G, La Villa G, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891-8.
7. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-7.
8. Kelbaek H, Eriksen J, Brynjolf I, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984;54:852-5.
9. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
10. Ma Z, Lee SS. Cirrhotic cardiomyopathy: Getting to the heart of the matter. Hepatology 1996;24:451-9.
11. Fernandez-Sola J, Estruch R, Grau JM, et al. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med 1994;120:529-36.
12. Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;22:326-32.
13. Ingles AC, Hernandez I, Garcia-Estan J, et al. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991;260:1912-17.
14. Harcombe AA, Ramsay L, Kenna JG, et al. Circulating antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci 1995;88:263-8.
15. Trevisani F, Sica G, Mainqua P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999;30:1387-92.
16. Chaudhry V, Corse AM, O'Brian R, et al. Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiological study. Hepatology 1999;29:1698-703.
17. Ma Z, Miyamoto A, Lee SS. Role of altered β-adrenoreceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996;110:1191-8.
18. 2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986;1:1409-11.
19. Zavecz JH, Bueno O, Maloney RE, et al. Cardiac excitation-contraction coupling in the portal hypertensive rat. Am J Physiol 2000;279:G28-39.
20. Moreau R, Komaichi H, Kirstetter P, et al. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-23.
21. Ward CA, Ma Z, Lee SS. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997;273:G537-44.
22. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongations in cirrhosis: prevalence, relationship with severity and aetiology of the disease and possible pathogenic factors. Hepatology 1998;27:28-34.
23. Jiménez W, Poo JL, Leivas A. Endothelin and systemic, renal and hepatic hemodynamic disturbances in cirrhosis. In: Arroyo V, Ginès P, Rodés J, eds. Ascites and renal dysfunction in liver disease. Pathogenesis diagnosis and treatment. London: Blackwell Science, 1999:291-303.
24. Ros J, Jimenez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995;21:554-60.
25. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
26. Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrine Invest 1998;21:170-9.
27. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
28. Dhingra H, Roongsritong C, Kurtzman NA. Brain natriuretic peptide: role in cardiovascular and volume homeostasis. Semin Nephrol 2002;22:423-37.
29. Gines P, Jimenez W, Arroyo V, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988;8:636-42.
30. La Villa G, Romanelli RG, Casini Raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992;16:156-61.
31. Wong F, Siu S, Liu P, et al. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis. Clin Sci 2001;101:621-8.
32. Henriksen JH, Gøtze JP, Fuglsang S, et al. increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7.
33. Goetze JP, Kastrup J, Pedersen F, et al. Quantification of pro-B-type natriuretic peptide and its products in human plasma by an analysis independent precursor processing. Clin Chem 2002;48:1035-42.